Evidence map›Paper›PMID 34062984›Full record

ArticleAntioxidants (Basel, Switzerland)2021

High Expression of SOD2 Protein Is a Strong Prognostic Factor for Stage IIIB Squamous Cell Cervical Carcinoma.

Maria Cecília Ramiro Talarico, Rafaella Almeida Lima Nunes, Gabriela Ávila Fernandes Silva, Larissa Bastos Eloy da Costa, Marcella Regina Cardoso, Sérgio Carlos Barros Esteves, Luis Otávio Zanatta Sarian, Luiz Carlos Zeferino, Lara Termini

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Maria Cecília Ramiro TalaricoDepartment of Obstetrics and Gynecology, Division of Gynecologic and Breast Oncology, School of Medical Sciences, State University of Campinas (UNICAMP-Universidade Estadual de Campinas), Campinas, São Paulo 13081970, Brazil.ORCID 0000-0003-1646-9754
Rafaella Almeida Lima NunesCentro de Investigação Translacional em Oncologia, Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo 05403911, Brazil.
Gabriela Ávila Fernandes SilvaCentro de Investigação Translacional em Oncologia, Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo 05403911, Brazil.
Larissa Bastos Eloy da CostaDepartment of Pathology, State University of Campinas (UNICAMP-Universidade Estadual de Campinas), Campinas, São Paulo 13083887, Brazil.
Marcella Regina CardosoDepartment of Obstetrics and Gynecology, Division of Gynecologic and Breast Oncology, School of Medical Sciences, State University of Campinas (UNICAMP-Universidade Estadual de Campinas), Campinas, São Paulo 13081970, Brazil.
Sérgio Carlos Barros EstevesDepartment of Radiotherapy, Division of Gynecologic and Breast Oncology, Women's Hospital Professor Doutor José Aristodemo Pinotti-Centro de Atenção Integral à Saúde da Mulher (CAISM), State University of Campinas (UNICAMP-Universidade Estadual de Campinas), Campinas, São Paulo 13083881, Brazil.
Luis Otávio Zanatta SarianDepartment of Obstetrics and Gynecology, Division of Gynecologic and Breast Oncology, School of Medical Sciences, State University of Campinas (UNICAMP-Universidade Estadual de Campinas), Campinas, São Paulo 13081970, Brazil.
Luiz Carlos ZeferinoDepartment of Obstetrics and Gynecology, Division of Gynecologic and Breast Oncology, School of Medical Sciences, State University of Campinas (UNICAMP-Universidade Estadual de Campinas), Campinas, São Paulo 13081970, Brazil.
Lara TerminiCentro de Investigação Translacional em Oncologia, Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo 05403911, Brazil.

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) 573799/2008-3Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) 2008/57889-1Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) 2010/07739-3Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) 2012/16059-1Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) 2015/26573-2
6 · The paper itself

Abstract

High superoxide dismutase 2 (SOD2) expression is associated with a poor prognosis at many cancer sites, the presence of metastases, and more advanced cervical cancer. This study aims to determine whether SOD2 protein expression is associated with the prognosis of stage IIIB cervical carcinoma.

methodssixty-three patients with stage IIIB squamous cell cervical carcinoma were included. The evaluation of SOD2 expression by immunohistochemistry was based on a positive cell ratio score and the staining intensity score. Taking disease recurrence and death as endpoints, receiver operating characteristic curves were used to discriminate between high and low SOD2 expression.

resultshigh SOD2 expression was associated with recurrence (

conclusionhigh SOD2 expression is a strong prognostic factor for stage IIIB squamous cell carcinoma of the cervix and could be used as a prognostic marker in women with cervical carcinoma.

Indexed as

antioxidantsbiomarkersprognosissuperoxide dismutase 2survival analysistumoruterine cervical neoplasms

Identifiers

PMID34062984
PMCPMC8147985

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.